Phathom reports Q4 net loss $55M; FDA meeting in March for vonoprazan resubmission

Phathom Pharmaceuticals, Inc.

2022-FY EPS reported -$5.05

Net loss Q4 2022 $55.0M vs $35.8M Q4 2021; full year net loss $197.7M vs $143.9M.
Cash $155.4M at Dec 31, 2022; additional $100M available under Hercules term loan.
FDA meeting scheduled March 2023 to discuss stability data and resubmission for erosive GERD and H. pylori NDAs.
Positive Phase 3 PHALCON-NERD-301 met primary endpoint (p<0.0001) for vonoprazan in non-erosive GERD.
Commercial launch on hold due to nitrosamine impurity; mitigation measures in place.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Phathom Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter ended December 31, 2022 was $55.0 million.

Period: the quarter and year ended December 31, 2022
Net income: Net loss for the fourth quarter ended December 31, 2022 was $55.0 million
Result: reported results

Exact text from the filing

On February 28, 2023, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-052344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.